Revenio Group Corporation Receives Marketing Authorization in the United States for Revenio Icare ic200 Intraocular Pressure Measurement Device
January 15, 2020 at 08:15 am
Share
Revenio Group Corporation announced that the Revenio Icare ic200 intraocular pressure measurement device has been granted marketing authorization in the United States.
Icare ic200, the new generation tonometer for intraocular pressure screening for professional use has been cleared by FDA, the Food and Drug Administration of the United States. The product has been previously authorized in both Europe and Japan. The FDA clearance now enables the launch of sales and marketing measures also in the United States. Icare ic200 is a fast, reliable, accurate and easy-to-use tonometer for intraocular pressure screening. Increased intraocular pressure is the only risk factor for glaucoma which can be influenced. This is why measurement of
intraocular pressure is so important. The special feature of Icare ic200 is that measurements can be performed in a seated, half-seated or recumbent position. For example, after cataract surgery, measuring intraocular pressure when the patient is in a lying position is an important part of the treatment process.
Revenio Group Oyj, formerly Done Solutions Oyj, is a Finland-based company primarily engaged in the health technology segment. The Companyâs activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. It distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.
REVENIO GROUP OYJ 
